_ Research & development Pipeline K-877 Pemafibrate K-321 Ripasudil K-877 Pemafibrate Pipeline Pemafibrate is drug that has been designed to selectively and potently activate a receptor in the nucleus of the cell called PPARα (Peroxisome proliferator-activated receptor, subtype alpha). Activation of the PPARα receptor leads to changes in the activity of a number of different genes in the nucleus, which in turn leads to a range of metabolic effects in the body. The main change is a reduction in the concentration of blood triglycerides, even in patients taking statins. Pemafibrate is licenced for use in Japan, as PARMODIA®, for the reduction of triglycerides, but is not yet approved for use in Europe and is currently undergoing clinical trials to assess its ability to reduce serious cardiovascular events in high risk populations. There is increasing evidence that triglycerides are associated with the risk of cardiovascular events such as heart attacks, stroke, and sudden death. The effect of pemafibrate on triglyceride concentrations, along with other beneficial effects on glucose metabolism and inflammation are expected to reduce the incidence of these events in patients who continue to be at risk of cardiovascular disease, despite statin therapy. A large clinical trial (the PROMINENT study) has recently recruited 10,000 patients from around the globe to determine the extent to which pemafibrate can reduce heart attacks, stroke, hospitalisations for heart disease, and cardiovascular death in patients taking statins who continue to have high triglyceride concentrations. If the trial is successful, then pemafibrate could be an important treatment for use alongside statins to prevent what is still one of the leading causes of death in Europe. Kowa are proud supporters of the Triglyceride Education and Research Forum, for more information on the importance of triglycerides click here https://www.triglycerideforum.org/ FAQs KOWA ALREADY HAS A LIPID LOWERING DRUG – PITAVASTATIN – WHY DO YOU NEED ANOTHER ONE? BLOOD LIPIDS THAT DON’T RESPOND WELL TO STATINS MUST BE RARE? DOES REDUCING TRIGLYCERIDES AND INCREASING HDL-C REDUCE CARDIOVASCULAR EVENT RATES? WHERE IS THE PROMINENT STUDY RUNNING? WHEN WILL THE RESULTS OF PROMINENT BE AVAILABLE? MAKE AN ENQUIRY Work with us For more information on our partnership opportunities please get in touch Latest publications Pemafibrate Improves Hepatic Inflammation, Function and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease : A One-Year Observational Study Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease? Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases PROMINENT study Efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα): Pooled analysis of phase 2 and 3 studies in dyslipidemic patients with or without statin combination. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study Long-Term efficacy and safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment. Effects of pemafibrate, a novel selective PPARa modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: A randomized, double-blind, placebo-controlled, phase 3 trial Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis Kowa Pharmaceutical Europe Co. Ltd. 105 Wharfedale Road Winnersh Triangle Wokingham Berkshire, RG41 5RB CONTACT US Our products Livazo Avansee Research & development Pipeline Pemafibrate K-877 Ripasudil K-321 Adverse event reporting Kowa routinely monitors the safety of all its medicines. This includes review of safety data from clinical studies, and collection of reports and cases of adverse events for marketed products. REPORT ADVERSE EVENT Copyrights © 2020 Kowa Pharmaceutical Europe Co. Ltd. All rights reserved. Date of preparation: 11 / 2020 UIN: KPE20 00002 Privacy policy Cookie policy Terms of use